DAWN
Price
$8.85
Change
-$1.49 (-14.41%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.06B
116 days until earnings call
Intraday BUY SELL Signals
HRMY
Price
$34.29
Change
+$0.75 (+2.24%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.93B
110 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DAWN vs HRMY

Header iconDAWN vs HRMY Comparison
Open Charts DAWN vs HRMYBanner chart's image
Day One Biopharmaceuticals
Price$8.85
Change-$1.49 (-14.41%)
Volume$59.7K
Capitalization1.06B
Harmony Biosciences Holdings
Price$34.29
Change+$0.75 (+2.24%)
Volume$4.99K
Capitalization1.93B
DAWN vs HRMY Comparison Chart in %
View a ticker or compare two or three
VS
DAWN vs. HRMY commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DAWN is a Hold and HRMY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (DAWN: $10.34 vs. HRMY: $33.54)
Brand notoriety: DAWN and HRMY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DAWN: 140% vs. HRMY: 96%
Market capitalization -- DAWN: $1.06B vs. HRMY: $1.93B
DAWN [@Biotechnology] is valued at $1.06B. HRMY’s [@Biotechnology] market capitalization is $1.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DAWN’s FA Score shows that 0 FA rating(s) are green whileHRMY’s FA Score has 0 green FA rating(s).

  • DAWN’s FA Score: 0 green, 5 red.
  • HRMY’s FA Score: 0 green, 5 red.
According to our system of comparison, both DAWN and HRMY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DAWN’s TA Score shows that 4 TA indicator(s) are bullish while HRMY’s TA Score has 5 bullish TA indicator(s).

  • DAWN’s TA Score: 4 bullish, 4 bearish.
  • HRMY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both DAWN and HRMY are a good buy in the short-term.

Price Growth

DAWN (@Biotechnology) experienced а +13.13% price change this week, while HRMY (@Biotechnology) price change was +6.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

DAWN is expected to report earnings on Mar 09, 2026.

HRMY is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HRMY($1.93B) has a higher market cap than DAWN($1.06B). HRMY YTD gains are higher at: -2.528 vs. DAWN (-18.390). HRMY has higher annual earnings (EBITDA): 265M vs. DAWN (-108.37M). HRMY has more cash in the bank: 565M vs. DAWN (453M). DAWN has less debt than HRMY: DAWN (3M) vs HRMY (172M). HRMY has higher revenues than DAWN: HRMY (773M) vs DAWN (188M).
DAWNHRMYDAWN / HRMY
Capitalization1.06B1.93B55%
EBITDA-108.37M265M-41%
Gain YTD-18.390-2.528727%
P/E RatioN/A10.58-
Revenue188M773M24%
Total Cash453M565M80%
Total Debt3M172M2%
TECHNICAL ANALYSIS
Technical Analysis
DAWNHRMY
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
Bearish Trend 17 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
DAWN
Daily Signal:
Gain/Loss:
HRMY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PJRCX9.520.08
+0.85%
PGIM Quant Solutions International Eq C
QMGRX13.570.08
+0.59%
Invesco Advantage International R
PFPRX65.400.16
+0.25%
Parnassus Mid Cap Growth Institutional
POGAX80.660.09
+0.11%
Putnam Large Cap Growth A
FFNIX14.32N/A
N/A
Fidelity Advisor Asset Manager 40% I

DAWN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DAWN has been loosely correlated with DNLI. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DAWN jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DAWN
1D Price
Change %
DAWN100%
-0.19%
DNLI - DAWN
47%
Loosely correlated
-0.34%
RVMD - DAWN
45%
Loosely correlated
+2.73%
OCUL - DAWN
45%
Loosely correlated
+2.41%
IDYA - DAWN
43%
Loosely correlated
-0.19%
NRIX - DAWN
43%
Loosely correlated
-5.37%
More

HRMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNBIF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNBIF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRMY
1D Price
Change %
HRMY100%
+1.70%
SNBIF - HRMY
52%
Loosely correlated
N/A
CYTK - HRMY
37%
Loosely correlated
-0.84%
BMRN - HRMY
35%
Loosely correlated
+0.71%
SYRE - HRMY
32%
Poorly correlated
+0.34%
DAWN - HRMY
31%
Poorly correlated
-0.19%
More